Evidence map›Paper›PMID 36242997›Full record

ArticleMed (New York, N.Y.)2022

Next generation T cell therapies for solid cancers.

John B Haanen, Ton N Schumacher

Abstract readComment
PubMed Publisher
In one paragraph

Article in Med (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

John B HaanenDivision of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; Department of Clinical Oncology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands. Electronic address: j.haanen@nki.nl.
Ton N SchumacherDivision of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; Department of Hematology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Leiden University Medical Center · NLOncode Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-infiltrating lymphocytes show consistent clinical benefit in metastatic melanoma, but they are a poorly defined product with variable antitumor activity. In this issue, Palmer et al.

Indexed as

Lymphocytes, Tumor-InfiltratingMelanomaHumansLymphocyte ActivationT-Lymphocytes

Identifiers

PMID36242997
OpenAlexW4306250713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.